|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Aeglea Biotherapeutics, Inc. (AGLE) |
|
|
$0.60 0.00 (0.00%) as of 4:30 Thu 9/7
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
64,229,000 |
| Market
Cap: |
38.58(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6007 - $0.6007 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 130 |
| Guru Rank Value : 9.2 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Aeglea BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biotechnology company developing human enzyme therapeutics for people with rare metabolic diseases. Co.'s development programs include: Pegzilarginase in Arginase 1 Deficiency, which is a recombinant human Arginase 1 that enzymatically degrades the amino acid arginine and improves the stability and arginine-degrading activity of the enzyme in human plasma; and AGLE-177 in Homocystinuria, which is a PEGylated, or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine. Co.'s preclinical pipeline includes cystinuria program to reduce plasma cystine and cysteine levels.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
25,531 |
3,461,011 |
| Total Sell Value |
$0 |
$0 |
$779,316 |
$779,316 |
| Total People Sold |
0 |
0 |
2 |
3 |
| Total Sell Transactions |
0 |
0 |
3 |
4 |
| End Date |
2025-03-27 |
2024-12-24 |
2024-06-25 |
2023-06-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Henderson Michael Thomas |
Director |
– • – |
2025-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
105,379 |
105,379 |
|
- |
|
| Albers Jeffrey W. |
Director |
– • – |
2024-11-06 |
4 |
AS |
$36.76 |
$246,313 |
I/I |
(6,700) |
27,360 |
|
- |
|
| Albers Jeffrey W. |
Director |
– • – |
2024-10-25 |
4 |
AS |
$36.43 |
$10,929 |
I/I |
(300) |
34,060 |
|
- |
|
| Burrows Scott L |
Chief Financial Officer |
• – – |
2024-09-03 |
4 |
S |
$28.17 |
$522,074 |
D/D |
(18,531) |
116,422 |
|
- |
|
| Harwin Peter Evan |
|
– • – |
2024-04-25 |
4 |
OE |
$0.00 |
$0 |
I/I |
3,639,680 |
4,018,101 |
|
- |
|
| Turtle Cameron |
Chief Executive Officer |
• • – |
2024-02-15 |
4 |
A |
$9.82 |
$3,928 |
D/D |
400 |
746,907 |
|
- |
|
| Harwin Peter Evan |
|
– • • |
2023-12-29 |
4 |
A |
$0.00 |
$0 |
I/I |
812,076 |
406,038 |
|
- |
|
| Harwin Peter Evan |
|
– • • |
2023-12-29 |
4 |
AS |
$0.00 |
$0 |
I/I |
(3,435,480) |
0 |
|
- |
|
| Burrows Scott L |
Chief Financial Officer |
• – – |
2023-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
134,953 |
134,953 |
|
- |
|
| Albers Jeffrey W. |
|
– • – |
2023-11-24 |
4/A |
A |
$0.00 |
$0 |
I/I |
34,360 |
34,360 |
|
- |
|
| Harwin Peter Evan |
|
– • • |
2023-11-24 |
4 |
A |
$0.00 |
$0 |
I/I |
3,435,480 |
3,435,480 |
|
- |
|
| Turtle Cameron |
Chief Executive Officer |
• • – |
2023-11-24 |
4 |
A |
$0.00 |
$0 |
D/D |
723,440 |
746,507 |
|
- |
|
| Harwin Peter Evan |
|
– • • |
2023-06-22 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9,460,540 |
|
32% |
|
| Turtle Cameron |
Chief Operating Officer |
• – – |
2023-06-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
576,699 |
|
32% |
|
| Neuman Linda L |
Chief Medical OfficerOfficer |
• – – |
2022-11-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,000 |
|
-78% |
|
| Souza Marcio |
Director |
– • – |
2022-08-25 |
4 |
B |
$0.56 |
$50,472 |
D/D |
90,000 |
90,000 |
2.39 |
-4% |
|
| Hanley Jr. Michael Conick |
Chief Commercial Officer |
• – – |
2022-06-08 |
4 |
B |
$0.71 |
$20,022 |
D/D |
28,200 |
36,200 |
2.74 |
- |
|
| Quinn Anthony |
President & CEO |
• • – |
2022-03-16 |
4 |
B |
$2.34 |
$187,705 |
D/D |
80,079 |
550,540 |
2.81 |
- |
|
| Quinn Anthony |
President & CEO |
• • – |
2022-03-15 |
4 |
B |
$1.86 |
$78,942 |
D/D |
42,417 |
473,461 |
2.81 |
- |
|
| Quinn Anthony |
President & CEO |
• • – |
2022-03-14 |
4 |
B |
$1.93 |
$130,221 |
D/D |
67,472 |
431,044 |
2.81 |
- |
|
| Alspaugh Jonathan |
Chief Financial Officer |
• – – |
2022-03-11 |
4 |
B |
$2.08 |
$156,000 |
D/D |
75,000 |
165,372 |
2.74 |
- |
|
| Quinn Anthony |
President & CEO |
• • – |
2022-03-11 |
4 |
B |
$2.06 |
$71,780 |
D/D |
34,777 |
363,572 |
2.81 |
- |
|
| Shanafelt Armen |
Director |
– • – |
2021-12-13 |
4 |
B |
$3.65 |
$53,600 |
D/D |
14,685 |
150,000 |
2.39 |
- |
|
| Shanafelt Armen |
Director |
– • – |
2021-12-10 |
4 |
B |
$3.65 |
$49,333 |
D/D |
13,516 |
135,315 |
2.39 |
- |
|
| Quinn Anthony |
President & CEO |
• • – |
2021-12-10 |
4 |
B |
$3.75 |
$39,473 |
D/D |
10,526 |
328,795 |
2.81 |
- |
|
96 Records found
|
|
Page 1 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
